Off-Label Prescribing in Children Remains High: A Call for Prioritized Research.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed.

1. Pre-prescription review system improves prescription safety, efficiency, and cost-effectiveness in pediatric outpatients: a western China study.Frontiers in pharmacology · 2025
   Article
2. Efficacy and Safety of Anti-Tumor Necrosis Factor Alpha in Very Early Onset Inflammatory Bowel Disease.Inflammatory bowel diseases · 2024
   Article
3. Optimizing therapeutic decision-making for off-label medicines use: A scoping review and consensus recommendations for improving practice and researchPharmacoepidemiology and drug safety · 2023
   Article
4. Utilization of Antitumor Necrosis Factor Biologics in Very Early Onset Inflammatory Bowel Disease: A Multicenter Retrospective Cohort Study From North America.Journal of pediatric gastroenterology and nutrition · 2022
   Article
5. A Sponsor's View on Postmarketing Regulatory Commitments Involving Human Drug Products.Clinical pharmacology and therapeutics · 2022
   Article
6. Systematic Data Monitoring and Analysis of Cardiovascular Off-label Prescriptions in Pediatrics: Focus on Angiotensin-Converting Enzyme Inhibitors (ACE-I) and Beta Blockers.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2022
   Article
7. Phase 0/microdosing approaches: time for mainstream application in drug development?Nature reviews. Drug discovery · 2020
   Review

Corrections and comments

• Comment on
  Trends in Off-Label Drug Use in Ambulatory Settings: 2006-2015.2019

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as